格隆汇3月9日｜通过卫星图像监测船舶动向的机构TankerTrackers.com称，伊朗仍在通过霍尔木兹海峡运送大量原油。该机构联合创始人Samir Madani表示，自2月28日战争爆发以来，伊朗至少已通过该水道运输1100万至1200万桶原油。实际数字可能更高，但由于冲突导致卫星数据获取存在延迟。由于TankerTrackers.com通过卫星图像进行监测，因此即便船只关闭数字应答器，也能捕捉到其航行动态。

格隆汇3月9日｜据知情人士透露，诺和诺德(NVO.US)与Hims & Hers Health Inc.(HIMS.US)即将握手言和，计划最早于周一宣布全新合作协议，这家丹麦制药商将授权在Hims平台销售其减肥药物，从而终结双方的公开对峙。受此消息提振，Hims股价在美股盘前一度暴涨55%，而诺和诺德则上涨约1%。据了解，双方曾在去年达成类似协议，但因Hims拒绝停止营销仿制药品，诺和诺德随即单方面终止合作。

正值全国两会时间，3月7日，海南代表团举行开放团组会议，会场显得比去年更为拥挤。 2025年12月18日，海南自贸港正式启动全岛封关运作，完成高水平对外开放的“关键一跃”。如今两个多月过去，外界都在关注：封关后的自贸港怎么样了？ 开放团组会议现场，全国人大代表、海南省委书记冯飞将之总结为16个字，即总体上“平稳有序、物畅其流、人享其行、流量聚集”。言下之意不难理解：海南已经初步通过了这场新的“压力测试”。 在稳步向前的潮水之下，企业的涌动更显湍急。作为被提问的全国人大代表之一，正大（海南）兴隆咖啡产业开发有限公司行政后勤部后勤主管黄海文难掩兴奋。在她的描述中，封关不仅带来了优惠、带来了商机，还让企业从中找到拓展边界的可能性。 政府工作报告指出，要扎实推进海南自由贸易港建设。全国人大代表，海南省人民政府党组成员、秘书长，机关党组书记、办公厅主任蔡强将封关后的感受形容为一种“推背感”，“就像行驶的汽车突然加速”。在他看来，这正是自贸港战略目标、政策机遇带来的快速前进动力。 01 现场“对账”，自贸港引力有多强 整场会议上，数字出现的频率格外高。 当被问及封关效果时，冯飞用“扩容”“赋能”两个关键词概括，每个词背后均是长长的一串数字。 “扩容”是指政策范围扩大。伴随零关税税目占全部商品税目的比例从封关前的21%增至74%，提高53个百分点，推动政策享惠主体新增备案超过1.1万家、进口货物货值同比增长1.55倍、离岛免税销售额增长30.9%。 图片来源：新华社 而“赋能”则体现在政策让自贸港对各类要素的吸引力增强。在政策组合优势推动下，海南新增经营主体5.1万户，其中新增企业4.1万户，增长43.6%；外资企业、备案外贸企业分别增长30%和74%。 除了与封关直接相关的增长外，一些连带效应同样出现。比如，封关让更多人将目光投向海南，体现在旅游上，在去年海南接待游客突破一亿人次、旅游总花费超过2000亿元的基础上，今年春节假期，海南游客及旅游消费分别增长28.9%和30.7%。 这样的目光更来自全球。过去两个多月间，叠加海南对86国免签政策，经对外开放口岸进出境海南的旅客达到65.3万人次，增长35%，其中免签入境达15.8万人次、增长53.7%。 事实上，仅就3月7日的会议来看，吸引的境外媒体记者同样不在少数。 自贸港封关的引力为何如此之强？整场会议上被提及的一个个具体案例...

据监测卫星影像以观察船舶动向的公司TankerTrackers.com 称，伊朗仍能继续通过霍尔木兹海峡这一航运咽喉要道运出大量原油。 该公司联合创始人Samir Madani表示，自2月28日战争爆发以来，德黑兰已通过该水道输送了至少1，100万至1，200万桶原油。他指出，实际数字可能更高，但由于冲突导致卫星资料传输延迟。 由于霍尔木兹海峡的航运基本上停摆，波斯湾大多数产油国无法将石油输送到全球市场，油价在周一一度飙升至每桶近120美元。 责任编辑：何云

Source: Bloomberg, 4:09

Welcome to Tech In Depth, our daily newsletter about the business of tech from Bloomberg’s journalists around the world. Today, Austin Carr looks at the question of how artificial intelligence will affect workers after major job cuts at financial tech company Block. Tech Across the Globe Oracle-OpenAI plans: Oracle and OpenAI have ended talks to lease an expansion of their Stargate artificial intelligence data center site in Texas. Meta is now in discussion to use the location. Social media bans: The move to keep young people off social media platforms has expanded to Indonesia and India. Pentagon-Anthropic dispute: The AI startup runs the risk of losing a wide range of US government business after the Defense Department declared it a supply chain security risk in a dispute over artificial intelligence safety guardrails. Revalued Startup AI chipmaker Cerebras has picked Morgan Stanley to lead its initial public offering in a renewed attempt to go public. The offering could raise about $2 billion in a listing as soon as April. The company, valued at $23 billion in a funding round earlier this year, withdrew its previous IPO registration in October. The future of work Last week, Block co-founder and chairman Jack Dorsey tried to do damage control after announcing that the financial tech firm was laying off 40% of its workforce , or about 4,000 employees. Dorsey attributed the job cuts to advances in artificial intelligence that have been enabling Block to increase productivity with smaller teams, but critics wondered whether he was really “ AI-washing ” layoffs that could otherwise be blamed on mismanagement and over-hiring. The debate soon spilled into social media as Dorsey publicly defended his decision and denied that Block, the maker of Square and Cash App, was bloated. Whether he was indeed deflecting or not, the drama demonstrates the challenges companies are having in balancing talk of the wild efficiencies afforded by this radically new technology with the co...

Rangsarit Chaiyakun/iStock via Getty Images Listen below or on the go via Apple Podcasts and Spotify G7 to discuss coordinated oil reserve release , FT says; dollar pulls back. (00:13) Live Nation ( LYV ) nears DOJ settlement that avoids Ticketmaster sale: report. (01:51) Alphabet ( GOOG ) ( GOOGL ) offers CEO pay deal worth up to $692M with stock price, Waymo incentives. (02:19) This is an abridged transcript. G7 finance ministers will reportedly discuss a possible joint release of petroleum from reserves coordinated by the International Energy Agency. The Financial Times reported that the leaders will have an emergency meeting today aimed at tackling the surge in oil prices following the conflict in the Gulf. According to people familiar with the situation, including a senior G7 official, the ministers and Fatih Birol, IEA executive director, will hold a call at 8.30am New York time to discuss the impact of the Iran war. Three G7 countries, including the U.S., have so far expressed support for the idea, according to the people familiar with the talks. The 32 members of the IEA hold strategic reserves as part of a collective emergency system designed for oil price crises. According to the FT report , one person indicated that certain U.S. officials see a 300 million–400 million barrel release, or 25–30% of the 1.2 billion barrel reserve, as reasonable. The price at the pump has risen greatly over the past week. According to AAA, the average price for a gallon of gas is $3.47. It was less than $3 before the war began. Meanwhile, South Korea’s president invokes the first fuel price ceiling in 30 years to combat war-driven energy shock . We’re also following reports that the Saudis are offering oil on the spot market as the war has disrupted contracted flows . Live Nation Entertainment ( LYV ) is reportedly close to settling a federal antitrust lawsuit accusing the company of illegally monopolizing the live music industry. Bloomberg News is reporting that the settleme...

The S&P 500 has gained 17% over the past year, and gold has dramatically outperformed it, up by more than 70%. However, silver has been the real story, with the "other" precious metal up by nearly 160%. In this video, I discuss why it has performed so well and 3 top ETFs to consider if you want silver exposure in your portfolio. *Stock prices used were the morning prices of March 4, 2026. The video was published on March 5, 2026. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » Should you buy stock in iShares Silver Trust right now? Before you buy stock in iShares Silver Trust, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and iShares Silver Trust wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $534,008!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,090,073!* Now, it’s worth noting Stock Advisor’s total average return is 949% — a market-crushing outperformance compared to 190% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors. See the 10 stocks » *Stock Advisor returns as of March 9, 2026. Matt Frankel, CFP has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Matthew Frankel is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through their link they will earn some extra mo...

Panview Capital Ltd trimmed its position in Alphabet Inc. (NASDAQ:GOOG - Free Report) by 78.1% in the third quarter, according to its most recent filing with the SEC. The fund owned 37,774 shares of the information services provider's stock after selling 135,000 shares during the period. Alphabet accounts for approximately 3.9% of Panview Capital Ltd's investment portfolio, making the stock its 8th biggest position. Panview Capital Ltd's holdings in Alphabet were worth $9,200,000 at the end of the most recent reporting period. Several other hedge funds also recently modified their holdings of GOOG. Robinson Smith Wealth Advisors LLC raised its position in Alphabet by 1.8% in the third quarter. Robinson Smith Wealth Advisors LLC now owns 2,070 shares of the information services provider's stock valued at $504,000 after purchasing an additional 36 shares during the last quarter. Searle & CO. boosted its position in Alphabet by 0.6% during the 3rd quarter. Searle & CO. now owns 5,703 shares of the information services provider's stock worth $1,389,000 after buying an additional 36 shares during the period. Navellier & Associates Inc. grew its holdings in Alphabet by 0.6% during the 3rd quarter. Navellier & Associates Inc. now owns 5,846 shares of the information services provider's stock worth $1,424,000 after acquiring an additional 36 shares during the last quarter. BankPlus Wealth Management LLC grew its holdings in Alphabet by 1.2% during the 3rd quarter. BankPlus Wealth Management LLC now owns 3,143 shares of the information services provider's stock worth $766,000 after acquiring an additional 37 shares during the last quarter. Finally, Activest Wealth Management increased its position in Alphabet by 0.5% in the 3rd quarter. Activest Wealth Management now owns 7,997 shares of the information services provider's stock valued at $1,948,000 after acquiring an additional 38 shares during the period. Institutional investors and hedge funds own 27.26% of the company's ...

Standoff with DoD over Claude chatbot reignites debate over how AI will be used in war – and who will be held accountable Until recently, Anthropic was one of the quieter names in the artificial intelligence boom. Despite being valued at about $350bn, it rarely generated the flashy headlines or public backlash associated with Sam Altman’s OpenAI or Elon Musk’s xAI. Its CEO and co-founder Dario Amodei was an industry fixture but hardly a household name outside of Silicon Valley, and its chatbot Claude lagged in popularity behind ChatGPT. That perception has shifted as Anthropic has become the central actor in a high-profile fight with the Department of Defense over the company’s refusal to allow Claude to be used for domestic mass surveillance and autonomous weapons systems that can kill people without human input. Amid tense negotiations, the AI firm rejected a Pentagon deadline for a deal last week, in a move that led Pete Hegseth, the defense secretary, to accuse Anthropic of “arrogance and betrayal” of its home country while demanding that any companies that work with the US government cease all business with the AI firm. Continue reading...

Nutshell Asset Management Ltd cut its holdings in Taiwan Semiconductor Manufacturing Company Ltd. (NYSE:TSM - Free Report) by 53.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 18,584 shares of the semiconductor company's stock after selling 21,581 shares during the period. Taiwan Semiconductor Manufacturing makes up 2.5% of Nutshell Asset Management Ltd's investment portfolio, making the stock its 13th biggest holding. Nutshell Asset Management Ltd's holdings in Taiwan Semiconductor Manufacturing were worth $5,190,000 as of its most recent SEC filing. Other hedge funds have also recently bought and sold shares of the company. Childress Capital Advisors LLC lifted its position in shares of Taiwan Semiconductor Manufacturing by 145.3% during the 3rd quarter. Childress Capital Advisors LLC now owns 3,192 shares of the semiconductor company's stock worth $891,000 after purchasing an additional 1,891 shares during the last quarter. Vanguard Personalized Indexing Management LLC lifted its holdings in shares of Taiwan Semiconductor Manufacturing by 9.4% during the third quarter. Vanguard Personalized Indexing Management LLC now owns 101,876 shares of the semiconductor company's stock worth $28,470,000 after buying an additional 8,738 shares during the last quarter. Hantz Financial Services Inc. boosted its position in shares of Taiwan Semiconductor Manufacturing by 28.6% in the third quarter. Hantz Financial Services Inc. now owns 37,216 shares of the semiconductor company's stock valued at $10,394,000 after acquiring an additional 8,284 shares during the period. Hollencrest Capital Management grew its stake in shares of Taiwan Semiconductor Manufacturing by 125.3% in the third quarter. Hollencrest Capital Management now owns 5,216 shares of the semiconductor company's stock worth $1,457,000 after acquiring an additional 2,901 shares during the last quarter. Finally, Cherok...

The large tortoiseshell – an elusive and enigmatic butterfly that became extinct in Britain in the last century – is a UK resident species once again, with a flurry of early spring sightings. Britain’s list of native butterflies has increased to 60 with the return of the insect after individuals emerged from hibernation in woodlands in Kent, Sussex, Hampshire, Dorset, Cornwall and the Isle of Wight. The sightings have led Butterfly Conservation to declare the large tortoiseshell (Nymphalis polychloros) a resident species in the UK – as opposed to a migratory one – for the first time in the charity’s 58-year history. “The signs are really positive, which is lovely,” said Richard Fox, head of science for Butterfly Conservation. “It is resident and therefore it is another species to add to Britain’s total, which is good news. It’s not well-established enough yet to say it’s definitely back for good and will be widespread across multiple landscapes – we’re still in that zone of uncertainty at the moment, but there are exciting signs.” Unlike the small tortoiseshell (Aglais urticae), which is found in gardens and whose caterpillars eat nettles, the large tortoiseshell is a tree-dwelling butterfly whose caterpillars feed on trees including elm, willow, aspen and poplar. View image in fullscreen A small tortoiseshell – with white patches near its wingtips that are not found on the larger species. Photograph: Ray Wilson/Alamy It is bigger, as its name suggests, and lacks the white markings found on its more widespread counterpart. The loss of elms due Dutch elm disease was once considered a factor in the large tortoiseshell’s extinction in the UK by the 1960s, but lepidopterists now believe Britain may have always been at the northerly limit of its natural range and the species’ return is now assisted by global heating. It last flourished in Britain during a run of fine summers in the 1940s, but in recent years growing numbers have migrated across the North Sea and the Chan...

In the shadow of Antwerp’s main arena, close to the city’s docklands, runs the Groot Schijn River. It was here that the body of Rita Roberts was discovered in June 1992, floating against the grate of a water treatment plant. She appeared to have been murdered, but Belgian police were unable to identify her. A tattoo of a black rose with green leaves and initials on her left arm was their only clue. Without knowing her name, police struggled for leads on who could have killed Roberts. Her case remained in limbo for almost three decades until police in the Netherlands realised that a large number of their own cold cases were also unidentified women, such as Roberts, who had been murdered or died in suspicious circumstances. View image in fullscreen Susan Hitchin, who leads the forensic DNA unit, at Interpol’s headquarters in Lyon. Photograph: Alexandre Bagdassarian/Guardian They suspected many were probably foreign nationals and perhaps victims of human trafficking, or with family in other countries who did not know they were missing – and that making progress with their investigations would require a cross-border approach. Dutch police contacted neighbouring Belgian and German forces and eventually Interpol about the possibility of an international appeal for information on the cases. It was this that brought Roberts’ and other unidentified death cases to the desk of Susan Hitchin, from the forensics team at Interpol’s headquarters in the French city of Lyon. In 2023, in an effort to locate family members and kickstart stalled investigations, Interpol launched Operation Identify Me and began publishing the details of dozens of women from across Europe who had been murdered or died in suspicious circumstances. Hitchin remembers the day that the message from Roberts’ family in the UK came through to her team. They had recognised her distinctive tattoo in news reports about the appeal. “It’s one of those [messages] that sends a shiver down your spine, because you can se...

Claes Bang plays the Danish designer of Paris’s Grande Arche in a meticulous drama about artistic purity colliding with bureaucratic ego and national vanity At first glance, Stéphane Demoustier’s new drama about the construction of Paris’s Arche de la Défense appears to belong to the recent run of what you might call French brand-heritage pictures, which include the likes of 2021’s Eiffel or 2023’s Widow Clicquot . But adapted from Laurence Cossé ’s 2016 novel La Grande Arche, the film is not the story of a cultural triumph but rather the testimony of a failure, or at least a monumental botch-job, that spiritually crushed its Danish architect, Johan Otto von Spreckelsen (played here by Claes Bang). In 1983, Von Spreckelsen was the unexpected winner of an international competition to design the statement building for the French capital’s western business district. He’s such an obscure name that the embassy in Denmark doesn’t even know who he is, leaving President Mitterrand’s adviser Jean-Louis Subilon (a toadying Xavier Dolan) to track him down while he’s fishing in a Danish lake. Summoned to France, this purist refuses to deviate from the perfect dimensions of his “Cube”, seeing it as the culmination of his life’s work. But he’s immediately caught between the pernickety caprices of the premier (Michel Fau) and the cost-cutting wiles of the technocrat Subilon. Continue reading...

Some of the largest US banks are considering suing their financial regulator, arguing that a new raft of licenses for crypto, payment and fintech could put American consumers and the wider financial system at risk. The Bank Policy Institute (BPI), which represents 40 of the biggest US lenders including JP Morgan, Goldman Sachs and Citigroup, is understood to be weighing its legal options after the Office of the Comptroller of the Currency (OCC) failed to heed repeated warnings from influential banking groups and state regulators over its reinterpretation of federal licensing rules. The OCC, which is led by Jonathan Gould, a Donald Trump appointee and former crypto executive, has effectively made it easier for crypto and fintech upstarts to secure and operate under a national bank trust charter, giving them the right to serve customers across all 50 states. However, banks say giving these firms the OCC’s stamp of approval means letting firms loose into the US financial system without the same rigorous supervision and controls required of fully fledged banks. The reforms brought forward by the OCC are widely seen as playing into the Trump administration’s ideological push to bring crypto and previously fringe financial firms into the mainstream. Trump’s own family-run cryptocurrency business, World Liberty Financial, made headlines after applying for one of the OCC’s national trust bank charters in January. Although bank lobby groups have so far stopped short of commenting on the firm’s bid for regulatory approval, the move has sparked opposition in Congress. The BPI in October urged the OCC to reject applications by crypto and blockchain firms Circle and Ripple, as well as London-headquartered payments firm Wise, all of which lodged applications for so-called national trust charters. The BPI, which has a board that includes JP Morgan boss Jamie Dimon, Bank of America’s Brian Moynihan, and Goldman Sachs chief David Solomon, warned at the time that “allowing firms to c...

Gerber Kawasaki Wealth & Investment Management Sells 19,035 Shares of Tesla, Inc. $TSLA MarketBeat

Our physiological response to emotions apparently lasts just a minute and a half. But there’s an embarrassing episode from 2009 that still makes me sweat I’ve just discovered the “90-second rule”, a concept neuroanatomist Dr Jill Bolte Taylor explored in her book, Whole Brain Living, back in 2021. That’s how long our physiological response to emotions such as anger lasts, from the time we formulate a thought to the point at which our blood is “completely clean” of the noradrenaline released in response to it, Bolte Taylor explained to a US news channel . I read about it in US magazine Bustle , which suggested a 90-second timeout could “reset your vibe”, reframing it, bleakly, as an alternative to a lunch break: “It often feels like a big ask to take an hour lunch … everyone can use just 90 seconds for a quick reset.” Presumably it’s back in the ether because Bolte Taylor appeared on Steven Bartlett’s podcast last November, explaining that if you’re still experiencing emotional reactions after 90 seconds, “you’re rethinking the thoughts.” Continue reading...

Luke, a blind Australian shepherd, came to us seven years ago, after we rescued him from a working horse farm. Even though he can’t see, Luke moves around with a fearlessness that is inspiring. He compensates with his other senses; Luke can smell and hear at an astonishing level, that’s how he notices things. But he also seems to understand that he’s going to run into things and be confused at times. That does not deter him in the slightest. View image in fullscreen ‘He seems to sense when you’re down’ … Luke and Linda Lopez Tabarez at Bubbling Springs park in California, 2020. Photograph: Steven R Tabarez Luke looks like the classic Australian shepherd – grey, white, brown and black with spots all over. His eyes are getting old and filmy but they have life in them. At home, he knows exactly where everything is and only bumps into things when he gets excited. We try to help by not moving things unnecessarily and by keeping things tidy, so he won’t trip over anything. Luke is always happy, smiles a lot, and seems to sense when you’re down. He often walks by other dogs without noticing them. Cats can easily outsmart him by sitting still and being quiet. One cat likes to let Luke find him and then the cat moves three feet to the left, and the hunt starts all over again. He tries to herd things and loves getting into the classic shepherd herding position, even though he’s only trying to guide pigeons who land on the lawn. He likes bones and getting scratched behind the ears. He dislikes loud noises – we live in California and the Fourth of July is his least favourite holiday because of all the fireworks. He’s taught us tolerance and acceptance at a time in our lives when we’re getting older and all the bad news happening in the world has made it harder to care. Luke always cares and reminds us we can too. View image in fullscreen ‘Different but able’ … painted portrait of Luke. Illustration: Steven R Tabarez Last year, when I had two heart attacks, Luke was distraught t...

格隆汇3月9日｜随着人工智能技术的突飞猛进，过去的“AI只能聊天”已成历史。近日，出现了一种新型“AI电子宠物”——OpenClaw，这款由奥地利工程师开发的智能体软件，被网友戏称为“数字龙虾”。它不仅能在电脑上自动完成复杂任务，甚至可以替你进行商务谈判和社交互动。然而，OpenClaw背后隐藏着巨大的成本危机。许多人发现，光是雇佣这样一名AI员工的“伙食费”就足以让人望而却步。数据显示，使用OpenClaw的成本远超普通的ChatGPT等传统AI。 与传统AI相比，OpenClaw的工作模式更像是一个高频的“读写刷卡机”。它在执行任务时，需要不断地读取、分析和生成大量的文本信息。由于AI模型是按“Token”来计费的，OpenClaw的运行模式导致其消耗的Token量惊人。 现实生活里，OpenClaw不止一次被网友比做是会“呼吸”的钞票。有网友的OpenClaw，一天“吃饭”需要花400块。还有开发者在测试类似OpenClaw的自动化智能体时，由于没有限制任务循环，且未开启“缓存省钱模式”，首月消耗了1.8亿个Token。按照当时高性能模型(含输入/输出权重)的综合单价计算，这笔账单最终高达2万多元人民币。而根据中金发布的数据，2025年度，只有0.05%的中国人月收入超过2万元。

微博接入KimiClaw 2026-03-09 19:00:26 来源： 同花顺7x24快讯 分享 文章提及标的 微博 -- AI智能体 -- 微博（WB）AI发文称，微博（WB）接入KimiClaw，用户可远程连接与控制ai智能体（886099）。

Representatives of China’s semiconductor industry are calling for stronger state backing in artificial intelligence chips and critical materials, aiming to fast-track core technology breakthroughs. During last week’s “two sessions” – the annual meetings of China’s top legislature and advisory body – scholars and entrepreneurs in the semiconductor sector urged Beijing to leverage the nation’s advantage in strategic chip raw materials and accelerate the commercial application of AI chips to secure a lead in the global tech race. Zhang Yunquan, a professor specialising in high-performance computing at the Chinese Academy of Sciences, said the government should take a greater role in regulating the prices of AI computing power, which is delivered by chips running in data centres for modern AI workloads. Advertisement “Competition among companies is fierce, with most resorting to low-price tactics, leading to ‘involutionary’ competition,” he told the South China Morning Post during the sessions, referring to cutthroat, low-quality price competition – prevalent in sectors ranging from electric vehicles (EVs) to food delivery – that Beijing has vowed to combat. Zhang, a member of the Chinese People’s Political Consultative Conference, suggested that the government could issue pricing guidelines on AI computing power. He proposed that the country establish a “unified trading market where computing power across the country can be traded uniformly”, making computing power “a commodity like electricity or oil”. Advertisement Hao Yue, a deputy to the National People’s Congress (NPC) and vice-president of Xidian University in Xian, Shaanxi province, highlighted China’s “industrial leverage” in rare earth elements.

This week, tens of thousands of game developers and producers will once again gather in San Francisco, as they have since 1988, for the weeklong Game Developers Conference. But this year’s show will be missing many international developers who say they no longer feel comfortable traveling to the United States to attend, no matter how relevant the show is to their work and careers. Dozens of those developers who spoke to Ars in recent months say they’re wary of traveling to a country that has shown a callous disregard for—or outright hostility toward—the safety of international travelers. That’s especially true for developers from various minority groups, those with transgender identities, and those who feel they could be targeted for outspoken political beliefs. “I honestly don't know anyone who is not from the US who is planning on going to the next GDC,” Godot Foundation Executive Director Emilio Coppola, who’s based in Spain, told Ars. “We never felt super safe, but now we are not willing to risk it.” Read full article Comments

With markets in crisis, it’s a good time to check in on our bear put spread screener. A bear put spread is a vertical spread that aims to profit from a stock declining in price. It has a bearish directional bias as hinted in the name. Unlike the bear call spread, it suffers from time decay so traders need to be correct on the direction of the underlying and also the timing. A bear put spread is created through buying an out-of-the-money put and selling a further out-of-the-money put. The maximum profit is equal to the distance between the strikes, less the premium paid. The loss is limited to the premium paid. Let’s take a look at Barchart’s Bear Put Spread Screener for today: Some interesting trades here with impressive Max Profit Percentage. Let’s take a look at the first item in the table – a bear put spread on Nvidia (NVDA). NVDA Bear Put Spread Example Using the May 15 expiry, this trade involves buying the $195 put and selling the $190 put. The price for the trade is $3.35 which means the trader would pay $335 to enter the trade. This is also the maximum loss. The maximum gain be calculated by taking the width between the strikes and subtracting the premium paid: 5 – 3.35 x 100 = $165. The breakeven price for the trade is equal to the long put strike, less the premium. In this case, that gives us a breakeven price of $191.65. Let’s look at another example. This time on Palantir (PLTR). Palantir Bear Put Spread Example The first Palantir bear put spread is also using the May 15 expiry and involves buying the $170 trike put and selling the $165 strike put. The cost of the trade is $320 which is also the maximum loss with the maximum possible gain being $180. The maximum gain would occur if Palantir stays below $170 on the expiration date. Let’s look at another example, this time on Oracle (ORCL). Oracle Bear Put Spread Example The Oracle trade is also using the May 15 expiry and involves buying the $165 strike put and selling the $160 strike put. The cost of the...

KOMODO-1 first-in-human clinical trial of BBI-940 open for enrollment $108 million in cash provides runway into the second half of 2028, through expected clinical proof-of-concept readout for KOMODO-1 SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD) , a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced financial results and business highlights for the fiscal quarter and full year ended December 31, 2025. "With the KOMODO-1 trial of BBI-940 actively enrolling, we are excited to evaluate this potentially first-in-class oral Kinesin degrader in patients with breast cancer who are seeking new treatment options. BBI-940 is designed to disrupt ecDNA segregation and inheritance, a differentiated mechanism for targeting chromosomally unstable cancers. The Boundless team is focused on clinical execution and reaching an initial proof-of-concept readout within our existing cash runway," said Zachary Hornby, President and Chief Executive Officer of Boundless Bio. Business Highlights and Upcoming Milestones BBI-940 novel Kinesin degrader program In January 2026, the U.S. Food and Drug Administration accepted the Company’s Investigational New Drug application for BBI-940, a novel, selective, oral Kinesin degrader. KOMODO-1 ( K inesin O ral Mo lecular D egrader for O ncology-1), a first-in-human clinical trial of BBI-940 in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative (ER+/HER2-) breast cancer who have progressed following treatment with a cyclin-dependent kinase 4 and/or 6 (CDK4/6) inhibitor plus endocrine therapy, as well as patients with triple-negative breast cancer luminal androgen receptor subtype (TNBC-LAR), is open for enrollment. inesin ral lecular egrader for ncology-1), a first-in-human clinical trial of BBI-940 in patients with estrogen recepto...

Lead candidate, EDIT-401, which demonstrated >90% mean LDL-C reduction in preclinical studies, remains on track for IND/CTA submission by mid-2026 Preparing to initiate Company’s first-in-human clinical trial in HeFH patients, with early human proof-of-concept data on track for year-end 2026 Strong cash position with cash runway into the third quarter of 2027 CAMBRIDGE, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today reported financial results for the fourth quarter and full year 2025 and provided business updates. “We achieved notable progress in the fourth quarter of 2025 as we advanced our mission and strategy to become a leader in in vivo gene editing,” said Gilmore O’Neill, M.B., M.M.Sc., President and Chief Executive Officer of Editas Medicine. “We continue to advance our lead in vivo development candidate, EDIT-401, an experimental, potential best-in-class, one-time therapy, which demonstrated significantly reduced mean LDL cholesterol levels of over 90 percent in preclinical studies. With cash runway into the third quarter of 2027, we are in a strong position to drive EDIT-401 toward upcoming milestones and look forward to submitting an IND/CTA by mid-2026 and initiating our first-in-human trial of EDIT-401 in patients living with heterozygous familial hypercholesterolemia (HeFH) later this year.” Recent Achievements and Upcoming Milestones Editas continues to advance its lead in vivo development candidate, EDIT-401, which has demonstrated the potential to reduce mean LDL cholesterol levels by more than 90 percent in non-human primates, and will present additional preclinical data by mid-2026. The Company remains on track to submit an IND/CTA for EDIT-401 by mid-2026. Editas is preparing to initiate a first-in-human clinical trial in patients with HeFH later this year, and the Company is on track to achieve early human ...

Enrollment continues to progress in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis Phase 2 TRITON trial of Descartes-08 in dermatomyositis and antisynthetase syndrome, expected to initiate in 1H26 Phase 1/2 HELIOS pediatric trial of Descartes-08 in juvenile dermatomyositis actively enrolling Approximately $126.9 million cash, cash equivalents and restricted cash as of December 31, 2025, expected to support planned operations into mid-2027, including completion of ongoing Phase 3 AURORA trial FREDERICK, Md., March 09, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (“we”, the “Company” or “Cartesian”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today reported financial results for the year ended December 31, 2025, and outlined recent business updates. “Building on a productive year, we look forward to a potentially transformative 2026 as we advance Descartes-08 across several autoimmune indications,” said Carsten Brunn, Ph.D., President and Chief Executive Officer of Cartesian. “Our top priority remains delivering on our Phase 3 AURORA trial in myasthenia gravis (MG), for which we are on track to enroll approximately 100 patients. This trial represents a crucial opportunity to demonstrate the potential of Descartes-08 to improve patient outcomes and redefine the standard-of-care for MG. Descartes-08’s ease of use, including, flexible, convenient outpatient administration with no preconditioning chemotherapy, combined with deep and durable responses observed through 12 months following a single course of treatment, and a favorable safety profile, underscore our belief that Descartes-08 holds significant promise to deliver meaningful benefit to patients.” Dr. Brunn continued, “Beyond MG, we are working to activate sites for our Phase 2 TRITON trial of Descartes-08 in myositis, which we plan to initiate in the first half of 2026. In parallel, we are also excited to explore potentially enha...

ROCK HILL, S.C., March 09, 2026 (GLOBE NEWSWIRE) -- 3D Systems Corporation (NYSE:DDD) announced today its financial results for the fourth quarter and full year ended December 31, 2025. Fourth quarter revenue of $106.3 million grew 16% sequentially, above guidance of 8% to 10% growth, driven by a successful ramp-up of new printer system sales and higher materials consumption For full year 2025, the Company delivered double-digit top-line growth in personalized health services and aerospace and defense markets Cost reduction and efficiency programs delivered approximately $55 million of annualized cost savings in 2025 The Company expects to continue its momentum in top-line growth and bottom-line performance in 2026 Summary of Financial Results (Unaudited) Three Months Ended Year Ended (in millions, except per share data) December 31, 2025 December 31, 2024 December 31, 2025 December 31, 2024 Revenue $ 106.3 $ 111.0 $ 386.9 $ 440.1 Gross profit 32.8 34.4 131.0 164.2 Gross profit margin 30.8 % 31.0 % 33.9 % 37.3 % Operating expense 55.4 64.8 227.1 441.6 Operating loss (22.7 ) (30.4 ) (96.1 ) (277.4 ) Net (loss) income attributable to 3D Systems Corporation (19.5 ) (33.7 ) 29.9 (255.6 ) Diluted (loss) income per share (0.15 ) (0.25 ) 0.19 (1.94 ) Non-GAAP measures for year-over-year comparisons Non-GAAP gross profit margin 31.0 % 31.3 % 34.3 % 37.4 % Non-GAAP operating expense 42.5 58.4 195.6 250.3 Adjusted EBITDA (5.3 ) (19.1 ) (45.4 ) (66.4 ) Non-GAAP diluted loss per share $ (0.13 ) $ (0.19 ) $ (0.37 ) $ (0.62 ) Summary Comments on Results Dr. Jeffrey Graves, President and CEO of 3D Systems said, "We are pleased with our fourth quarter performance, which exceeded our expectations driven by both our Healthcare and Industrial segments. Three markets were particularly noteworthy: med tech, dental, and aerospace and defense, which are rapidly adopting 3D printing as a core manufacturing method. These three markets have been a particular focus for our new product develop...

TORONTO, March 09, 2026 (GLOBE NEWSWIRE) -- Constellation Software Inc. (TSX:CSU) (“Constellation” or the “Company”) today announced its financial results for the fourth quarter and year ended December 31, 2025 and declared a $1.00 per share dividend payable on April 15, 2026 to all common shareholders of record at close of business on March 27, 2026. This dividend has been designated as an eligible dividend for the purposes of the Income Tax Act (Canada). Please note that all dollar amounts referred to in this press release are in U.S. Dollars unless otherwise stated. The following press release should be read in conjunction with the Company’s annual Consolidated Financial Statements, prepared in accordance with IFRS Accounting Standards (“IFRS”) and our annual Management’s Discussion and Analysis for the year ended December 31, 2025, which can be found on SEDAR+ at www.sedarplus.com and on the Company’s website www.csisoftware.com. Additional information about the Company is also available on SEDAR+ at www.sedarplus.com. Q4 2025 Headlines: Revenue grew 18% (6% organic growth, 2% after adjusting for changes in foreign exchange rates) to $3,177 million compared to $2,703 million in Q4 2024. Net income attributable to common shareholders decreased 61% to $110 million ($5.19 on a diluted per share basis) from $285 million ($13.44 on a diluted per share basis) in Q4 2024. A number of acquisitions were completed for aggregate cash consideration of $472 million (which includes acquired cash). Deferred payments associated with these acquisitions have an estimated value of $99 million resulting in total consideration of $571 million. Other net investments of $321 million were completed, including the Company’s net investment in Asseco Poland S.A. Cash flows from operations (“CFO”) was $788 million, an increase of 16%, or $110 million, compared to $678 million for the comparable period in 2024. Free cash flow available to shareholders 1 (“FCFA2S”) was $423 million, a decrea...

Harry You is currently Chairman of dMY Squared Technology Group, Inc. and a member of Broadcom’s board of directors. Previously, he was lead independent director of IonQ Inc., a leading quantum computing hardware company. He is also an experienced public company officer, having held CFO roles at Accenture plc and Oracle Corporation, and an EVP role at EMC Corporation, among others. Peter Oey is the Chief Financial Officer of Grab, a prominent Southeast Asia superapp. He previously served as CFO of LegalZoom.com Inc. prior to its IPO and as CFO of MyLife.com Inc. Earlier in his career he held several finance leadership roles at Activision Blizzard Inc. Danielle Lambert was the VP of Human Resources at Apple, where she helped build out teams behind the iPod, iPhone, iPad and Apple Retail Stores, among others. She later played a pivotal role in the founding of Nest Labs Inc., as an investor and advisor through the company’s rapid growth and acquisition by Alphabet Inc. "Horizon Quantum is entering a crucial next phase of growth as we prepare to go public via a definitive business combination agreement with dMY," said Horizon Quantum Founder & CEO Dr Joe Fitzsimons. "Bringing world-class appointments to our board and leadership team strengthens the company and enhances our ability to achieve our mission of unlocking the full potential of quantum computers." Following the completion of Horizon Quantum’s merger (the "Business Combination") with dMY Squared Technology Group, Inc. ("dMY"), the company expects to make the following appointments to its board of directors: Danielle Lambert, formerly of Apple Inc. ("Apple"), Peter Oey of Grab Holdings Ltd. ("Grab"), Jill Turner of Broadcom Inc. ("Broadcom"), and Harry You, Chairman of dMY. Finally, in May of this year, Horizon Quantum will also fill out its leadership team, adding Catherine Fitzsimons, currently of Fidelity International Ltd. ("Fidelity"), as the company’s Chief Legal and Compliance Officer, EVP of Strategic In...

Experimental eye drug keeps nearly half of patients retreatment-free 6 months Stock Titan